Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients With Cushing's Disease.
DG
PitNET
SG
corticotroph tumors
densely and sparsely granulated pituitary tumors
electron microscopy
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
02
2021
accepted:
30
04
2021
entrez:
17
6
2021
pubmed:
18
6
2021
medline:
21
12
2021
Statut:
epublish
Résumé
Cushing's disease is the most common cause of endogenous hypercortisolemia due to a corticotroph pituitary tumor. Up-to-date there is no reliable biomarker of invasiveness among corticotroph tumors, while it is well established in the literature that sparsely granulated somatotroph tumors are characterized by poorer prognosis. The aim of the study was to correlate multiple data including clinical, biochemical, radiological, and pathological findings (including granulation pattern) as well as immediate post-operative remission status among patients operated on due to corticotroph tumors. We enrolled all patients consecutively operated on for planned transsphenoidal neurosurgery due to corticotroph PitNETs in years 2010-2018. We excluded from analysis silent corticotroph tumors, plurihormonal PitNETs, and the Crooke's cell adenomas. We recorded 348 hormonally active corticotroph PitNETs. The results of the analysis showed the female predominance 79.88% (n = 278), with the mean age of Cushing's disease occurrence 43.27 years of age. The mean time from the first signs and symptoms to the operation was 2 years. The women were diagnosed earlier (20-40 years of age Our study indicates that DG corticotroph adenomas occurred at younger age, more commonly were microadenomas as compared to SG tumors, less frequently had invasive features in comparison to SG corticotroph adenomas (p = 0.0019**), and more commonly achieved an immediate postsurgical hormonal remission (p = 0.0180*). We highlight the need for an accurate differentiation of DG and SG subtypes in the pathomorphological diagnosis of corticotropic tumors, especially in invasive PitNETs.
Identifiants
pubmed: 34135861
doi: 10.3389/fendo.2021.672178
pmc: PMC8202403
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
672178Informations de copyright
Copyright © 2021 Rak, Maksymowicz, Pękul and Zieliński.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Acta Neuropathol. 2006 Jan;111(1):1-7
pubmed: 16328527
Eur J Endocrinol. 2013 Oct 08;169(5):715-23
pubmed: 23996696
J Clin Endocrinol Metab. 2001 Jan;86(1):117-23
pubmed: 11231987
J Clin Endocrinol Metab. 2004 Aug;89(8):3818-20
pubmed: 15292311
Endocr Pract. 2018 Oct 2;24(10):907-914
pubmed: 30084690
Neurosurgery. 1993 Oct;33(4):610-7; discussion 617-8
pubmed: 8232800
Endocr J. 2012;59(3):221-8
pubmed: 22200580
Pituitary. 2013 Dec;16(4):490-8
pubmed: 23184260
N Engl J Med. 1994 Sep 8;331(10):629-36
pubmed: 8052272
Acta Neuropathol. 2017 Oct;134(4):521-535
pubmed: 28821944
J Clin Endocrinol Metab. 2003 Jun;88(6):2527-33
pubmed: 12788849
Endocr Pathol. 2019 Jun;30(2):118-127
pubmed: 30706322
Zh Vopr Neirokhir Im N N Burdenko. 2015;79(6):107-114
pubmed: 27008712
Am J Med. 1952 Nov;13(5):597-614
pubmed: 12996538
J Clin Pathol. 2006 Dec;59(12):1245-53
pubmed: 17142570
Turk Patoloji Derg. 2019;35(1):9-14
pubmed: 30035294
Clin Endocrinol (Oxf). 2012 Jan;76(1):96-102
pubmed: 21722151
Pituitary. 2017 Aug;20(4):450-463
pubmed: 28432562
Front Horm Res. 2004;32:146-74
pubmed: 15281345
Acta Neuropathol. 2006 Jan;111(1):76-7
pubmed: 16328520
Brain Tumor Pathol. 2018 Apr;35(2):57-61
pubmed: 29318396
Brain Pathol. 2012 Jul;22(4):443-53
pubmed: 22697380
Eur J Endocrinol. 2013 Mar 15;168(4):491-9
pubmed: 23288882
Clin Epidemiol. 2015 Apr 17;7:281-93
pubmed: 25945066
Mod Pathol. 2018 Jun;31(6):900-909
pubmed: 29434339
Pituitary. 2018 Apr;21(2):194-202
pubmed: 29305680
Endokrynol Pol. 2020;71(2):116-125
pubmed: 32154573
Clin Neurol Neurosurg. 2009 Jun;111(5):442-9
pubmed: 19200645
Virchows Arch. 2019 Dec;475(6):687-692
pubmed: 31578606
J Clin Endocrinol Metab. 2008 Feb;93(2):358-62
pubmed: 18056770
Diagnostics (Basel). 2020 Apr 16;10(4):
pubmed: 32316225
Endocrine. 2017 Apr;56(1):10-18
pubmed: 27189147
Endokrynol Pol. 2016;67(3):283-91
pubmed: 26884303
Cancers (Basel). 2020 Feb 22;12(2):
pubmed: 32098443
Eur J Endocrinol. 2016 Apr;174(4):539-49
pubmed: 26811407
Clin Endocrinol (Oxf). 1994 Apr;40(4):479-84
pubmed: 8187313
Rev Endocr Metab Disord. 2020 Jun;21(2):243-251
pubmed: 32504268
J Cell Mol Med. 2018 Mar;22(3):2023-2027
pubmed: 29314715
Lancet. 2006 May 13;367(9522):1605-17
pubmed: 16698415
Trends Endocrinol Metab. 2007 May-Jun;18(4):167-74
pubmed: 17412607
Am J Surg Pathol. 2003 Oct;27(10):1330-6
pubmed: 14508394
J Clin Endocrinol Metab. 1999 Aug;84(8):2664-72
pubmed: 10443657